← All stories
Markets
Why AstraZeneca (LSE:AZN) Tezspire Trial Matters Now
Highlights Tezspire met the main goals of a late-stage swallowing disorder study. Trial findings showed improvements in inflammation and swallowing symptoms. AstraZeneca plans to share detailed findings with regulators. AstraZeneca has repo…
Covered by 1 outlet
All coverage · 1 article